InvestorsHub Logo
Followers 7
Posts 1577
Boards Moderated 0
Alias Born 02/27/2014

Re: None

Tuesday, 12/16/2014 3:37:33 PM

Tuesday, December 16, 2014 3:37:33 PM

Post# of 80868
the optimist point of view regarding dilution might have some merit

Let's face it....allowed compensation in stocks is negotiated between Frost and other lead investors on one side and the management and board on the other side.

It is all about give and take, each side trying to achieve what it wants under a fair deal.

So, these initial levels of dilution might not last forever....unless Musclepharm finances all it's projects through Frost and co.

Even if that was the case, Frost usually brings a lot to the table...so it is not all bad. However, I don't think that is the case as Brad seems to be very much against raising more capital at a steep discount.

So, our fears might be misguided and Musclepharm might treat shareholders better than what we think. The share price is close to $8...it should matter to the management after a year with 80% sales growth and lots of shares awarded to management.

In 2015, the management is forced to deliver something to shareholders to survive.